Scientific Sessions 2025  /  Defining Success in EP Clinical Trials  /  VANISH2 Trial: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
Logo

American Heart Association

  79
  0

Final ID:

VANISH2 Trial: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia

  • Sapp, John  ( QEII HEALTH SCIENCES CENTRE , Halifax , Nova Scotia , Canada )
    • Author Disclosures:
    John Sapp: DO have relevant financial relationships ; Consultant:Varian:Active (exists now) ; Research Funding (PI or named investigator):Johnson & Johnson:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Defining Success in EP Clinical Trials

Friday, 11/07/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Mortality or bust: what makes for a meaningful VT trial outcome?

Stevenson William, Gerstenfeld Edward

AF burden, time to recurrent AF, or quality of life: how the choice of endpoint impacts our field.

Albert Christine, Winterfield Jeffrey

More abstracts from these authors:
In-Depth: VANISH2: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy

Sapp John

Acceptability and Effectiveness of a Novel, Video-Based CPR and AED Education Program in Canadian Schools

Allan Katherine, Dhillon Santokh, Mcculloch Holly, Ruether Kim, Zotzman Jeanine, Blanchard Ian, Janczyszyn Mike, Wong Natalie, Oneil Emma, Sapp John

You have to be authorized to contact abstract author. Please, Login
Not Available